none
Conditions
Interventions
Oxytocin will be administered intranasally to healthy subjects, [11C]AZ10419369 injection solution will be administered and a brain PET scan will be performed. In addition, assessment of social behavi
Sponsors
Yamasue Hidenori
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Males between the ages of 18 and 55 at the time consent is obtained (2) Total intelligence quotient > 80 (3) Individuals who have given their written consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Has been diagnosed with a mental illness (2) Use of psychotropic drugs in the past 6 months (3) History of hypersensitivity to oxytocin (4) History of epileptic seizures or head trauma with loss of consciousness for more than 5 minutes (5) History of alcohol-related or other substance-related disorders (6) Taking anti-inflammatory medications, which cannot be discontinued from one month prior to study drug administration (Visit 1) until Visit 2 or the end of the study (7) Has a family history of male breast cancer (8) Patients with a serious medical condition (9) Have a drug allergy, food allergy, or a specific constitution (10) Who cannot give consent to use contraception during the study period (11) Participate in any other research or clinical research (except for research involving PET imaging using [11C]DPA713) and receive any medication within 120 days prior to obtaining consent (12) Other subjects deemed ineligible for this study by the Principal Investigator(s).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PET measurement: Binding potential (BP)ND of [11C]AZ10419369 | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of social behavior: number of friend / foe judgments based on nonverbal information during Verbal Non-verbal Test (VnV) and their reaction time and gazing time on eye region. | — |
Contacts
Public ContactYosuke Kameno
Hamamatsu University School of Medicine
Outcome results
None listed